콘텐츠로 건너뛰기
Merck

H2775

DL-threo-β-Hydroxyaspartic acid

동의어(들):

threo-2-Amino-3-hydroxysuccinic acid

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

보기 변경

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):
C4H7NO5
CAS 번호:
Molecular Weight:
149.10
PubChem Substance ID:
eCl@ss:
32160406
UNSPSC Code:
12352106
NACRES:
NA.32
EC Number:
224-299-4
MDL number:
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의


Quality Level

storage temp.

−20°C

SMILES string

N[C@H]([C@@H](O)C(O)=O)C(O)=O

InChI

1S/C4H7NO5/c5-1(3(7)8)2(6)4(9)10/h1-2,6H,5H2,(H,7,8)(H,9,10)/t1-,2-/m1/s1

InChI key

YYLQUHNPNCGKJQ-JCYAYHJZSA-N

Gene Information

human ... GLUL(2752)
mouse ... GLUL(14645)

General description

DL-threo-β-hydroxyaspartic acid (THA) is a glutamate uptake inhibitor.

Application

DL-threo-β-Hydroxyaspartic acid (THA) has been used to block glutamate transport in cannulated sprague dawley rat.


저장 등급

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문



A Hirata et al.
Brain research, 771(1), 37-44 (1998-02-12)
Excitotoxicity secondary to the loss of glutamate transporters (GluT) has been proposed as a possible pathogenetic mechanism for neuronal degeneration in amyotrophic lateral sclerosis. We therefore investigated whether prolonged in vivo pharmacologic inhibition of GluT would result in neuronal damage
Ewa Nagańska et al.
Folia neuropathologica, 48(1), 35-44 (2010-04-13)
Erythropoietin (EPO) is a chemokine hormone that is widely distributed throughout the body including nervous system. For last years its role as cytokine involved in many physiological processes out of the bone marrow has been suggested. Moreover, it plays a
Nina Bionda et al.
Amino acids, 42(1), 285-293 (2010-11-18)
A simple and practical general synthetic protocol towards orthogonally protected tHyAsp derivatives fully compatible with Fmoc solid-phase peptide synthetic methodology is reported. Our approach includes enantioresolution of commercially available D: ,L: -tHyAsp racemic mixture by co-crystallization with L: -Lys, followed